Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

15.73 -0.13 (-0.82%)
Streaming Delayed Price Updated: 12:41 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Adaptive Biotechnologies Corporation - Common Stock

< Previous 1 2 3 Next >
News headline image
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Announces IVDR Certification for clonoSEQ® in European Union
clonoSEQ is the first IVDR-certified test to detect minimal residual disease in patients with lymphoid malignancies 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Second Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports First Quarter 2024 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
Announces CFO transition 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces New Translational Collaboration to Measure Minimal Residual Disease with clonoSEQ® Assay Across BeiGene’s Lymphoid Malignancy Pipeline
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancers 
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Report Second Quarter Financial Results on August 2, 2023
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Highlights New Data at ASCO 2023 and EHA 2023 Underscoring the clonoSEQ® Assay’s Impact as a Standard for Minimal Residual Disease Assessment in Patients with Hematologic Cancer
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From Adaptive Biotechnologies
Via GlobeNewswire
News headline image
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
The T-Cell Therapy product candidate contains a neoantigen-specific T-cell receptor (TCR) identified and characterized through Adaptive’s TCR discovery platform 
From Adaptive Biotechnologies
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.